Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Large Increase in Short Interest

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 938,810 shares, an increase of 453.3% from the June 15th total of 169,677 shares. Currently, 4.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 5,496,954 shares, the short-interest ratio is currently 0.2 days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Vestor Capital LLC lifted its stake in shares of Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the period. Yorkville Advisors Global LP purchased a new stake in shares of Jupiter Neurosciences in the fourth quarter valued at $135,000. Geode Capital Management LLC grew its position in shares of Jupiter Neurosciences by 27.8% in the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock valued at $135,000 after purchasing an additional 28,826 shares during the period. Finally, Allen Capital Group LLC acquired a new position in Jupiter Neurosciences in the fourth quarter valued at $31,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Jupiter Neurosciences Stock Performance

NASDAQ:JUNS traded down $0.01 during mid-day trading on Friday, hitting $0.19. 641,407 shares of the company’s stock traded hands, compared to its average volume of 3,405,302. The firm’s 50 day simple moving average is $0.26 and its 200 day simple moving average is $0.49. Jupiter Neurosciences has a 1 year low of $0.17 and a 1 year high of $3.33. The company has a market cap of $6.89 million, a PE ratio of -0.70 and a beta of 1.73.

Jupiter Neurosciences (NASDAQ:JUNS) last posted its earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.23 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.